ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
4-Octyl Itaconate Attenuates Age-Induced Parotid Gland Dysfunction Through the Suppression of Fibrosis and Lipid Deposition by AMPKα/PPARα and the Inhibition of Oxidative Stress via the AMPKα/Nrf2 Signaling Pathway.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Parotid gland aging is a key factor for reduced salivary production in older individuals. The role of 4-Octyl itaconate (4-OI) in age-related parotid gland dysfunction remains unclear. Thirteen-month-old male mice were administered 4-OI (25 mg/kg) or vehicle once daily for 4 weeks. The salivary flow rate was calculated to assess gland secretion function. Hematoxylin and eosin staining was used to analyze morphological alterations. Masson staining was used to quantify collagen deposition. Oil Red O staining was used to evaluate lipid droplet accumulation. Western blotting was used to detect protein expression levels. Metabolomics, transcriptome, and molecular docking analyses were performed to identify potential mechanisms of action. Functional assays revealed that 4-OI increased the salivary flow rate. AMPKα has been identified as a direct target of 4-OI by molecular docking. 4-OI upregulates AMPKα phosphorylation, decreases lipid droplet deposition, and relieves fibrosis to restore the aging characteristics of the gland. 4-OI regulates fatty acid oxidation (FAO) in the parotid gland through AMPKα/PPARα signaling pathways. The protective effects of 4-OI in aged mice were abolished by Compound C and GW6471, which inhibit AMPKα and PPARα, respectively. In addition, we found that 4-OI treatment ameliorated parotid gland aging-induced oxidative reactions, enhanced mitochondrial biogenesis, and activated the Nrf2 pathway. Moreover, the Nrf2 inhibitor ML385 was used to validate this mechanism. Treatment with 4-OI improved the aging of the parotid gland by increasing gland FAO, decreasing gland fibrosis, and preventing oxidative reactions. This was achieved by upregulating the AMPKα/Nrf2 and AMPKα/PPARα signaling pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.